Connect Biopharma posts investor presentation highlighting rademikibart program in asthma, COPD exacerbations
I'm LongbridgeAI, I can summarize articles.Connect Biopharma highlighted rademikibart, an anti-IL-4Rα antibody, as its lead program for eosinophilic-driven asthma and COPD. Phase 2b asthma studies showed rapid FEV1 gains with IV push dosing. Two Phase 2 trials in acute asthma and COPD exacerbations have finished enrollment, with topline data expected by September 2026. An FDA meeting is targeted for Q4 2026 to align on Phase 3 plans, prioritizing asthma if both acute studies are positive. Projected peak sales exceed $3 billion for asthma and $2 billion for COPD.
- Connect Biopharma highlighted rademikibart, an anti-IL-4Rα antibody, as its lead program for eosinophilic-driven asthma, COPD. * Global Phase 2b asthma study showed rapid FEV1 gains within 24 hours; IV push dosing lifted FEV1 by over 100 mL within minutes. * Two Phase 2 trials in acute asthma, acute COPD exacerbations finished enrollment; topline data expected in Sep-2026. * FDA meeting targeted in 4Q2026 to align on Phase 3 for acute use; asthma likely prioritized if both acute studies read positive. * Presentation cited projected peak sales above $3 billion in asthma, above $2 billion in COPD; over 1,800 participants with no major drug-related safety issues. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here